| Isaac P Reeve, MD | |
|
888 Swift Blvd, Richland, WA 99352-3514 | |
| (509) 946-4461 | |
| Not Available |
| Full Name | Isaac P Reeve |
|---|---|
| Gender | Male |
| Speciality | Diagnostic Radiology |
| Experience | 16 Years |
| Location | 888 Swift Blvd, Richland, Washington |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1245475037 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 2085R0202X | Radiology - Diagnostic Radiology | MD60448032 (Washington) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Providence Health Center | Waco, TX | Hospital |
| Coryell Memorial Healthcare System | Gatesville, TX | Hospital |
| Ohiohealth Mansfield Hospital | Mansfield, OH | Hospital |
| Freestone Medical Center | Fairfield, TX | Hospital |
| Hamilton General Hospital | Hamilton, TX | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Central Texas Radiological Associates Pa | 4385740141 | 21 |
| Riverside Radiology And Interventional Associates Inc | 8729976964 | 206 |
News Archive
A University of Iowa study shows that loss or chemical inhibition of a protein, known as acid sensing ion channel protein (ASIC1a), reduces innate fear behavior in lab animals, making normally timid mice relatively fearless.
Bristol-Myers Squibb Company and Otsuka Pharmaceutical Co., Ltd. announced today that the U.S. Food and Drug Administration (FDA) has approved the supplemental New Drug Application (sNDA) for ABILIFY® (aripiprazole) for the treatment of irritability associated with autistic disorder in pediatric patients ages 6 to 17 years, including symptoms of aggression towards others, deliberate self-injuriousness, temper tantrums, and quickly changing moods.
Cancer researchers have discovered a previously unknown type of gene regulation and DNA behavior in breast cancer cells that may lead to better insight about environmental exposure to estrogen-like compounds. A new study, published in the journal Genome Research by researchers at The Ohio State University Comprehensive Cancer Center-Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC-James), provides the first evidence that cells can regulate many genes at once by looping their DNA, contributing to cancer when it goes awry. In this study, the gene regulation was discovered in breast cancer cells as a response to the hormone estrogen and resulted in the silencing of 14 genes at one time.
Exelixis, Inc. today announced preliminary results from BRIM7, an ongoing Phase Ib trial conducted by Roche and Genentech, Exelixis' collaborator and a member of the Roche Group, of the BRAF inhibitor (BRAFi) vemurafenib in combination with the MEK inhibitor GDC-0973 in patients with locally advanced/unresectable or metastatic melanoma carrying a BRAFV600 mutation.
› Verified 2 days ago
| Entity Name | Central Texas Radiological Associates Pa |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1861452864 PECOS PAC ID: 4385740141 Enrollment ID: O20070511000036 |
News Archive
A University of Iowa study shows that loss or chemical inhibition of a protein, known as acid sensing ion channel protein (ASIC1a), reduces innate fear behavior in lab animals, making normally timid mice relatively fearless.
Bristol-Myers Squibb Company and Otsuka Pharmaceutical Co., Ltd. announced today that the U.S. Food and Drug Administration (FDA) has approved the supplemental New Drug Application (sNDA) for ABILIFY® (aripiprazole) for the treatment of irritability associated with autistic disorder in pediatric patients ages 6 to 17 years, including symptoms of aggression towards others, deliberate self-injuriousness, temper tantrums, and quickly changing moods.
Cancer researchers have discovered a previously unknown type of gene regulation and DNA behavior in breast cancer cells that may lead to better insight about environmental exposure to estrogen-like compounds. A new study, published in the journal Genome Research by researchers at The Ohio State University Comprehensive Cancer Center-Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC-James), provides the first evidence that cells can regulate many genes at once by looping their DNA, contributing to cancer when it goes awry. In this study, the gene regulation was discovered in breast cancer cells as a response to the hormone estrogen and resulted in the silencing of 14 genes at one time.
Exelixis, Inc. today announced preliminary results from BRIM7, an ongoing Phase Ib trial conducted by Roche and Genentech, Exelixis' collaborator and a member of the Roche Group, of the BRAF inhibitor (BRAFi) vemurafenib in combination with the MEK inhibitor GDC-0973 in patients with locally advanced/unresectable or metastatic melanoma carrying a BRAFV600 mutation.
› Verified 2 days ago
| Entity Name | Riverside Radiology And Interventional Associates Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1093718496 PECOS PAC ID: 8729976964 Enrollment ID: O20181203000880 |
News Archive
A University of Iowa study shows that loss or chemical inhibition of a protein, known as acid sensing ion channel protein (ASIC1a), reduces innate fear behavior in lab animals, making normally timid mice relatively fearless.
Bristol-Myers Squibb Company and Otsuka Pharmaceutical Co., Ltd. announced today that the U.S. Food and Drug Administration (FDA) has approved the supplemental New Drug Application (sNDA) for ABILIFY® (aripiprazole) for the treatment of irritability associated with autistic disorder in pediatric patients ages 6 to 17 years, including symptoms of aggression towards others, deliberate self-injuriousness, temper tantrums, and quickly changing moods.
Cancer researchers have discovered a previously unknown type of gene regulation and DNA behavior in breast cancer cells that may lead to better insight about environmental exposure to estrogen-like compounds. A new study, published in the journal Genome Research by researchers at The Ohio State University Comprehensive Cancer Center-Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC-James), provides the first evidence that cells can regulate many genes at once by looping their DNA, contributing to cancer when it goes awry. In this study, the gene regulation was discovered in breast cancer cells as a response to the hormone estrogen and resulted in the silencing of 14 genes at one time.
Exelixis, Inc. today announced preliminary results from BRIM7, an ongoing Phase Ib trial conducted by Roche and Genentech, Exelixis' collaborator and a member of the Roche Group, of the BRAF inhibitor (BRAFi) vemurafenib in combination with the MEK inhibitor GDC-0973 in patients with locally advanced/unresectable or metastatic melanoma carrying a BRAFV600 mutation.
› Verified 2 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Isaac P Reeve, MD 888 Swift Blvd, Richland, WA 99352-3514 Ph: (509) 946-4461 | Isaac P Reeve, MD 888 Swift Blvd, Richland, WA 99352-3514 Ph: (509) 946-4461 |
News Archive
A University of Iowa study shows that loss or chemical inhibition of a protein, known as acid sensing ion channel protein (ASIC1a), reduces innate fear behavior in lab animals, making normally timid mice relatively fearless.
Bristol-Myers Squibb Company and Otsuka Pharmaceutical Co., Ltd. announced today that the U.S. Food and Drug Administration (FDA) has approved the supplemental New Drug Application (sNDA) for ABILIFY® (aripiprazole) for the treatment of irritability associated with autistic disorder in pediatric patients ages 6 to 17 years, including symptoms of aggression towards others, deliberate self-injuriousness, temper tantrums, and quickly changing moods.
Cancer researchers have discovered a previously unknown type of gene regulation and DNA behavior in breast cancer cells that may lead to better insight about environmental exposure to estrogen-like compounds. A new study, published in the journal Genome Research by researchers at The Ohio State University Comprehensive Cancer Center-Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC-James), provides the first evidence that cells can regulate many genes at once by looping their DNA, contributing to cancer when it goes awry. In this study, the gene regulation was discovered in breast cancer cells as a response to the hormone estrogen and resulted in the silencing of 14 genes at one time.
Exelixis, Inc. today announced preliminary results from BRIM7, an ongoing Phase Ib trial conducted by Roche and Genentech, Exelixis' collaborator and a member of the Roche Group, of the BRAF inhibitor (BRAFi) vemurafenib in combination with the MEK inhibitor GDC-0973 in patients with locally advanced/unresectable or metastatic melanoma carrying a BRAFV600 mutation.
› Verified 2 days ago
Timothy S Gormley, MD Radiology Medicare: Medicare Enrolled Practice Location: 888 Swift Blvd, Richland, WA 99352 Phone: 509-946-4611 | |
Scott Hammersmith, M.D. Radiology Medicare: Not Enrolled in Medicare Practice Location: 888 Swift Blvd, Richland, WA 99352 Phone: 509-943-5616 Fax: 509-943-9272 | |
Edward M Iuliano, DO Radiology Medicare: Accepting Medicare Assignments Practice Location: 888 Swift Blvd, Richland, WA 99352 Phone: 509-943-5616 Fax: 509-943-9272 | |
Shawn R Jones, MD Radiology Medicare: Accepting Medicare Assignments Practice Location: 888 Swift Blvd, Richland, WA 99352 Phone: 509-943-5616 Fax: 509-943-9272 | |
Dwane T Brittain, M.D. Radiology Medicare: Accepting Medicare Assignments Practice Location: 888 Swift Blvd, Richland, WA 99352 Phone: 509-943-5616 Fax: 509-943-9272 | |
Dr. Sean Christopher Koskinen, M.D. Radiology Medicare: Accepting Medicare Assignments Practice Location: 888 Swift Blvd, Richland, WA 99352 Phone: 509-943-5616 Fax: 509-943-9272 |